Omnicell Files 8-K on Executive Changes and Financials

TL;DR

Omnicell 8-K: Exec changes, director elections, and financial updates filed 8/25.

AI Summary

Omnicell, Inc. filed an 8-K on August 25, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate governance and financial reporting activities for the company.

Why It Matters

This filing provides insight into potential leadership changes and compensation structures at Omnicell, which can impact the company's strategic direction and investor confidence.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing executive and director changes, not indicating any immediate financial distress or significant operational shifts.

Key Players & Entities

• OMNICELL, INC. (company) — Registrant
• August 25, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value OMCL NASDAQ Global Select M
• $525,000 — ompensated at an initial base salary of $525,000 per annum. In addition, upon approval b
• $1,000,000 — award with a grant date target value of $1,000,000 in the form of restricted stock units (
• $1,150,000 — RSUs with a grant date target value of $1,150,000, one-third (1/3) of which will vest fol

Filing Documents

• tm2524232d1_8k.htm (8-K) — 30KB
• tm2524232d1_ex99-1.htm (EX-99.1) — 13KB
• tm2524232d1_ex99-1img01.jpg (GRAPHIC) — 23KB
• 0001104659-25-082526.txt ( ) — 243KB
• omcl-20250825.xsd (EX-101.SCH) — 3KB
• omcl-20250825_lab.xml (EX-101.LAB) — 33KB
• omcl-20250825_pre.xml (EX-101.PRE) — 22KB
• tm2524232d1_8k_htm.xml (XML) — 3KB

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2025, Omnicell, Inc. ("Omnicell" or the "Company") announced that Baird Radford, age 55, has been appointed Executive Vice President and Chief Financial Officer of the Company, effective August 26, 2025. A press release announcing the change in the Executive Vice President and Chief Financial Officer position is attached as Exhibit 99.1 hereto and incorporated herein by reference. Prior to joining Omnicell, Mr. Radford served as Chief Financial Officer of Allakos, Inc., a biotech company developing monoclonal antibodies for individuals with chronic conditions, from April 2021 to May 2025. From January 2020 to February 2021, Mr. Radford served as Senior Vice President of Finance of Aimmune Therapeutics Inc., exiting following the acquisition of the company by Nestle Health Science. From July 2014 to January 2020, Mr. Radford served as Chief Financial Officer of HeartFlow, Inc., a commercial-stage software services company using artificial intelligence for diagnosing and managing coronary artery disease. Prior to HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, Inc. and held various roles at eBay Inc., including Vice President of European Finance as well as Vice President Corporate Controller and Chief Accounting Officer. Mr. Radford began his professional career in the audit practice of PricewaterhouseCoopers after receiving his Bachelor of Business Administration degree from Ohio University. There are no arrangements or understandings between Mr. Radford and any other persons pursuant to which Mr. Radford was appointed as an executive officer of the Company. There are no family relationships between Mr. Radford and any director or executive officer of the Company. There are not any transactions or relationships between the Company and Mr. Radford that would requ

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release entitled "Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer" dated August 25, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. OMNICELL, INC. Date: August 25, 2025 /s/ Corey J. Manley Corey J. Manley Executive Vice President and Chief Legal and Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR